PERRIGO to Present at Upcoming Consumer Investor Conference

Dublin, May 19, 2022 /PRNewswire/ — Perrigo Company plc (NYSE: PRGO), the leading supplier consumer self-care products, announced today, President and Chief Executive Officer, Murray S. Kessler and CFO Eduardo Bezera Plan to attend an investor conference at the Credit Suisse HALO Investment Summit New York City exist Wednesday, May 25th. There will be no formal presentation.

President and Chief Executive Officer, Murray S. Kessler Also planned to attend the Oppenheimer Consumer Growth and E-Commerce Conference virtually Wednesday 15 Juneth exist 9:45AM ET.

Interested parties can visit the webcast on the Perrigo website:

About Perrigo

Perrigo Company plc (NYSE; PRGO) is a leading supplier Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance personal well-being by empowering consumers to proactively prevent or treat diseases that they can manage themselves. Led by its consumer self-care strategy, Perrigo is the largest U.S. store-brand OTC company in the categories it competes in and a top 10 U.S. revenue OTC company. Europe. Visit Perrigo Online

forward-looking statements

Certain statements in this press release are “forward-looking statements.” These statements relate to future events or the company’s future financial performance and involve known and unknown risks, uncertainties and other factors that could cause the actual results, levels of activity, performance or achievements of the company or its industry to differ materially from those expressed difference or implied by any forward-looking statement.In certain instances, forward-looking statements can be identified by terms such as “may,” “will,” “could,” “will,” “should,” “expect,” “forecast,” “plan,” “anticipate,” “intend” , “believe,” “estimate,” “predict,” “potential,” or the negative of these or other similar terms. The company makes these forward-looking statements based on its current expectations, assumptions, estimates and projections. Although the company believes that these expectations , assumptions, estimates and projections are reasonable, but these forward-looking statements are projections only and involve known and unknown risks and uncertainties, many of which are beyond the company’s control, including: the impact of the epidemic and its variants and related supply chains on the company’s business; general economic, credit and market conditions; the impact of the war on Ukraine and any escalation, including the impact of economic and political sanctions U.S., U.K., the European Union and other relevant countries; outbreaks or escalation of conflicts in other regions where we do business; future impairment charges; customer acceptance of new products; competition from other industry players, some of whom are in certain product categories having greater marketing resources or a larger market share than the company; pricing pressure from customers and consumers; addressing uncertain tax positions, including the company’s draft and final notices of proposed assessments issued by the IRS (“NOPA ”), and the effect on operating performance, cash flow and liquidity of the adverse outcome of any such litigation; pending and potential third-party claims and lawsuits, including lawsuits related to the company’s restatement of previously filed financial information and Litigation related to uncertain tax status, including NOPA; potential impact of ongoing or future government investigations and regulatory initiatives; potential cost and reputational impact of product recalls or sales suspensions; changes in tax reform legislation and/or healthcare policy impact; the timing, amount and cost of any share repurchase; fluctuations in currency exchange rates and interest rates; the company’s ability to realize the expected benefits from the sale of its Rx business, and potential costs or liabilities incurred or retained in connection with the transaction that may exceed the company’s estimates or expectations The risk of adverse effects on the company’s business or operations; the risk of inaccurate estimates of the company’s ability to realize the expected benefits of the acquisition of HRA Pharma and the company’s synergies or the company’s exposure to higher-than-expected integration or other costs associated with the acquisition; related to the HRA Pharma integration risks, including the risk that growth rates will be adversely affected by delays in the integration of sales and distribution networks; the completion and success of other announced and unannounced acquisitions or dispositions, and the company’s ability to realize expected benefits; and the company’s execution and realization of announced Capability of cost reduction efforts and expected benefits of strategic and other initiatives. An adverse outcome of the Company’s appeal of any material pending tax assessments or pending litigation (including securities or drug pricing matters) may ultimately require the use of Company assets to pay such assessments, damages claimed by third parties and associated interest and/or penalties , and any such use of Company assets will limit the assets available for other Company purposes.These and other important factors, including those discussed under “Risk Factors” on the company’s Form 10-K for the year ended December 31, 2021, and the company’s subsequent filings with the Securities and Exchange Commission, could cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date of this press release, and unless otherwise required by applicable securities laws, the company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information , future events or otherwise.

SourcePerrigo Company plc

Leave a Reply

Your email address will not be published. Required fields are marked *